, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today the appointment of
Christine A. White
, M.D., to its board of directors. Dr. White replaces Professor
Paul J. Nestel
, who has served as a director since
"Dr. White brings a unique and valuable perspective to our board as we continue to build a world-class oncology organization here in the U.S.," said
Daniel P. Gold
, Ph.D., President and Chief Executive Officer of
. "Her deep understanding of drug development and regulatory affairs coupled with her years of experience treating patients as a clinical oncologist will be a valuable asset to the company."
Dr. White was with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global Medical Affairs, where she played an integral role in the clinical development, regulatory affairs and commercialization of oncology drugs Rituxan® and Zevalin®. Previously, she served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in
, and in the Department of Medicine at Scripps Memorial Hospitals in
, most recently as Chairman.
Dr. White currently serves as a member of the board of directors of Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, and Genoptix, a specialized laboratory services provider. She also served as a director of Pharmacyclics, a biopharmaceutical company, and Monogram Biosciences, a life sciences company, until its acquisition by LabCorp in
. Dr. White earned her B.A. in Biology and her M.D. from the
University of Chicago
and is Board certified in both Internal Medicine and Medical Oncology.
"I am very pleased to welcome Dr. White to the board and look forward to working with her as we strive to build long-term shareholder value," said Professor
Bryan R.G. Williams
, Chairman of the board of directors of
. "I also want to take this opportunity on behalf of the entire board to thank Professor Nestel for his years of dedicated service to
About Marshall Edwards, Inc.
, Inc. (NASDAQ: MSHL) is a
-based oncology company focused on the clinical development of novel anti-cancer therapeutics. These derive from an investigational isoflavone technology platform, which has generated a number of novel compounds characterized by direct targeting of tumor metabolism. Specifically, these compounds are believed to target an enzyme present in the cell membrane of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell.
has licensed rights from Novogen Limited (ASX: NRT; Nasdaq: NVGN) for oncology drug candidates Phenoxodiol, Triphendiol, NV-143 and NV-128. For more information, please visit
Rituxan is a registered trademark of Genentech.